MI is developing a novel modality for noninvasive, low cost detection of early stage Left Ventricular Dysfunction (LVD-one of the most common preconditions leading to HF) and Heart Failure, as well as, monitoring of CHF patients. The company is developing a noninvasive, lightweight armband that monitors several parameters. The data is sent out and analyzed on MI's servers in order to provide a risk score for LVD/HF. The device is intended to be utilized for early detection purposes at PCPs' clinics as well as additional medical facilities in order to detect patients at the earliest stages of these conditions and provide them with deterioration preventing pharmaceutical therapies. The monitoring solution is intended to be utilized at CHF patients' home environment in order to provide a predictive indication of deterioration/lung congestion so that preventive measures can be executed (mostly pharmaceutical therapies) and readmission rates be decreased....
MI is developing a novel modality for noninvasive, low cost detection of early stage Left Ventricular Dysfunction (LVD-one of the most common preconditions leading to HF) and Heart Failure, as well as, monitoring of CHF patients. The company is developing a noninvasive, lightweight armband that monitors several parameters. The data is sent out and analyzed on MI's servers in order to provide a risk score for LVD/HF. The device is intended to be utilized for early detection purposes at PCPs' clinics as well as additional medical facilities in order to detect patients at the earliest stages of these conditions and provide them with deterioration preventing pharmaceutical therapies. The monitoring solution is intended to be utilized at CHF patients' home environment in order to provide a predictive indication of deterioration/lung congestion so that preventive measures can be executed (mostly pharmaceutical therapies) and readmission rates be decreased.
More information